Cencora (NYSE:COR) Given New $405.00 Price Target at Leerink Partners

Cencora (NYSE:COR) had its target price hoisted by Leerink Partners from $388.00 to $405.00 in a research report sent to investors on Thursday morning,Benzinga reports. They currently have an outperform rating on the stock.

COR has been the topic of several other reports. Wall Street Zen raised Cencora from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $330.00 target price on shares of Cencora in a research report on Tuesday, September 8th. Weiss Ratings raised Cencora from a “buy (b-)” rating to a “buy (b)” rating in a research note on Tuesday, October 6th. Morgan Stanley raised their price target on Cencora from $346.00 to $377.00 and gave the company an “overweight” rating in a report on Friday, October 30th. Finally, Evercore reaffirmed an “outperform” rating and issued a $350.00 price objective (up from $330.00) on shares of Cencora in a research note on Thursday, August 6th. Thirteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $368.73.

Cencora Stock Performance

COR opened at $339.58 on Thursday. The company has a debt-to-equity ratio of 3.01, a quick ratio of 0.58 and a current ratio of 0.94. The stock has a market capitalization of $64.80 billion, a price-to-earnings ratio of 18.95, a PEG ratio of 1.84 and a beta of 0.58. The company has a fifty day moving average of $324.83 and a 200 day moving average of $317.36. Cencora has a fifty-two week low of $244.82 and a fifty-two week high of $377.54.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $4.66 EPS for the quarter, topping the consensus estimate of $4.58 by $0.08. Cencora had a net margin of 1.03% and a return on equity of 110.72%. The business had revenue of $88.35 billion for the quarter, compared to analysts’ expectations of $87.95 billion. During the same quarter in the previous year, the company earned $3.84 EPS. The business’s quarterly revenue was up 5.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Cencora will post 19.53 earnings per share for the current fiscal year.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 30th. Shareholders of record on Friday, November 13th will be paid a $0.66 dividend. This represents a $2.64 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend is Friday, November 13th. This is an increase from Cencora’s previous quarterly dividend of $0.60. Cencora’s dividend payout ratio is 14.73%.

Insider Buying and Selling at Cencora

In other news, EVP Elizabeth Campbell sold 11,300 shares of the company’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the sale, the executive vice president directly owned 19,455 shares in the company, valued at approximately $6,305,754.60. This represents a 36.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.38% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Cencora

Several large investors have recently added to or reduced their stakes in COR. Fifth Third Bancorp lifted its position in Cencora by 18.4% in the third quarter. Fifth Third Bancorp now owns 77,837 shares of the company’s stock valued at $23,370,000 after purchasing an additional 12,112 shares during the last quarter. Maryland State Retirement & Pension System raised its position in shares of Cencora by 12.7% in the 3rd quarter. Maryland State Retirement & Pension System now owns 11,410 shares of the company’s stock worth $3,426,000 after acquiring an additional 1,289 shares in the last quarter. Jacobi Capital Management LLC grew its position in shares of Cencora by 4.9% in the 3rd quarter. Jacobi Capital Management LLC now owns 1,138 shares of the company’s stock worth $342,000 after buying an additional 53 shares during the period. First Command Advisory Services Inc. boosted its position in shares of Cencora by 322.6% in the 3rd quarter. First Command Advisory Services Inc. now owns 1,086 shares of the company’s stock worth $326,000 after purchasing an additional 829 shares in the last quarter. Finally, Machina Capital S.A.S. bought a new stake in Cencora in the third quarter worth $2,685,000. 97.52% of the stock is owned by institutional investors.

Cencora News Roundup

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Cencora reported fiscal Q4 adjusted EPS of $4.66, above the $4.58 consensus, while revenue of $88.35 billion also topped expectations and grew 5.5% year over year. Fiscal 2026 results
• Positive Sentiment: Management forecast fiscal 2027 adjusted EPS of $19.40–$19.75, signaling continued earnings growth. Specialty-drug demand was a key contributor to results. Fiscal 2027 outlook
• Positive Sentiment: Leerink Partners raised its price target to $405 and maintained an “outperform” rating. Cencora also increased its quarterly dividend 10%, to $0.66 per share. Cencora earnings coverage
• Neutral Sentiment: Cencora is reorganizing its reporting into two segments to sharpen focus and visibility. The change may help investors assess performance, but its effect on execution remains to be seen. Organizational changes
• Negative Sentiment: Reports linked the share weakness to Cardinal Health’s earnings beat, which may have shifted investor attention toward the competitor’s results. Cencora and Cardinal Health shares

About Cencora

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical sourcing and distribution company. It provides branded, generic and specialty pharmaceuticals, over-the-counter products and related health care supplies to pharmacies, hospitals, health systems, physician practices and other health care providers.

The company also offers services to pharmaceutical and biotechnology manufacturers, including logistics, commercialization support, market access, consulting, clinical trial support and patient assistance programs.